Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic investment totaling USD 20 million from global pharmaceutical leader Sanofi (NASDAQ: SNY) and Perceptive Xontogeny Venture Fund (PXV Fund I). This investment is a significant component of Zucara’s USD 20 million Series B financing round, highlighting the confidence of industry giants in Zucara’s innovative approach to diabetes management.
Strategic Investment and Exclusive Rights
As part of this strategic deal, Sanofi, the French pharmaceutical major, has earned an exclusive priority negotiation right concerning Zucara’s lead product, ZT-01, a somatostatin receptor 2 (SSTR2) antagonist. This positions Sanofi at the forefront of potential future collaborations and negotiations regarding the development and commercialization of ZT-01.
Advancing ZT-01: A Promising Treatment for Hypoglycemia
ZT-01 is engineered to prevent dangerous low blood glucose levels by restoring the body’s natural counterregulatory response to hypoglycemia. The recent funding will be instrumental in supporting the continuation of an ongoing Phase IIa study. This study is evaluating the efficacy of ZT-01 in reducing nocturnal hypoglycemic events in patients with type 1 diabetes, a critical area of focus in improving the quality of life for those living with the condition.-Fineline Info & Tech
Leave a Reply